May Hill Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

May Hill Capital’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19,939	Closed	-$48.9K	–	208
2025 Q2	$48.9K	Buy	+19,939	New	+$101K	0.02%	192

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

May Hill Capital's RCKT Position: Q3 2025 in Review

May Hill Capital sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 19,939 shares — an estimated $48.9K sold.

May Hill Capital first reported a position in RCKT in Q2 2025 and held it in 1 quarter. The position peaked at $48.9K in Q2 2025. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

May Hill Capital reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
May Hill Capital sold 19,939 Rocket Pharmaceuticals shares in Q3 2025, an estimated $48.9K.
May Hill Capital first reported a position in Rocket Pharmaceuticals in Q2 2025 and held it in 1 quarter.
May Hill Capital's Rocket Pharmaceuticals position peaked at $48.9K in Q2 2025.
173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on May Hill Capital's 13F filing for Q3 2025, filed 7 Nov 2025.